We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+19.63%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.55B
AUM Growth
+$1.04B
Cap. Flow
+$118M
Cap. Flow %
1.81%
Top 10 Hldgs %
51.69%
Holding
171
New
48
Increased
43
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$177M
2
BMY icon
Bristol-Myers Squibb
BMY
+$109M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$96.7M
4
INSP icon
Inspire Medical Systems
INSP
+$91.9M
5
COGT icon
Cogent Biosciences
COGT
+$76M

Top Sells

Rank Stock Value
1
OSCR icon
Oscar Health
OSCR
+$250M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$74.9M
3
BAX icon
Baxter International
BAX
+$47.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$42.6M
5
UTHR icon
United Therapeutics
UTHR
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.55%
2 Real Estate 0.38%
3 Financials 0.07%
4 Consumer Staples 0.07%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
51
Ventas
VTR
$48.7B
$24.8M 0.38%
354,000
– –
BBNX
52
Beta Bionics
BBNX
$713M
$23.2M 0.35%
1,168,415
– –
XENE icon
53
Xenon Pharmaceuticals
XENE
$6.36B
$21.8M 0.33%
542,020
– –
TSHA icon
54
Taysha Gene Therapies
TSHA
$1.59B
$17.6M 0.27%
5,386,000
– –
CGEM icon
55
Cullinan Oncology
CGEM
$1.07B
$17.4M 0.27%
2,927,013
-928,539
-24% -$6.8M
FHTX icon
56
Foghorn Therapeutics
FHTX
$305M
$15.9M 0.24%
3,255,514
– –
MNPR icon
57
Monopar Therapeutics
MNPR
$739M
$13M 0.2%
+159,765
New +$7.14M
EWTX icon
58
Edgewise Therapeutics
EWTX
$4.48B
$12.4M 0.19%
765,694
-1,301,626
-63% -$18.5M
OMDA
59
Omada Health Inc
OMDA
$1.22B
$12.2M 0.19%
553,107
– –
TOI icon
60
The Oncology Institute
TOI
$519M
$11.7M 0.18%
3,360,052
– –
IART icon
61
Integra LifeSciences
IART
$1.52B
$11.4M 0.17%
794,865
– –
GPCR icon
62
Structure Therapeutics
GPCR
$3.46B
$10.5M 0.16%
373,407
– –
SYRE icon
63
Spyre Therapeutics
SYRE
$8.69B
$10.3M 0.16%
613,665
– –
DCGO icon
64
DocGo
DCGO
$62.2M
$6.29M 0.1%
4,622,708
-318,857
-6% -$483K
SI
65
Shoulder Innovations Inc
SI
$435M
$6.06M 0.09%
+482,572
New +$6.74M
JBIO
66
Jade Biosciences
JBIO
$1.21B
$4.58M 0.07%
531,163
– –
ALGN icon
67
Align Technology
ALGN
$12B
$4.11M 0.06%
32,789
+30,844
+1,586% +$4.83M
PBH icon
68
Prestige Consumer Healthcare
PBH
$2.39B
$4.03M 0.06%
+64,563
New +$4.49M
CALC icon
69
CalciMedica
CALC
$11.1M
$4M 0.06%
1,300,000
– –
UFPT icon
70
UFP Technologies
UFPT
$1.92B
$3.72M 0.06%
18,660
+17,143
+1,130% +$3.77M
KIDS icon
71
OrthoPediatrics
KIDS
$509M
$3.6M 0.05%
194,109
+178,623
+1,153% +$3.68M
VREX icon
72
Varex Imaging
VREX
$463M
$3.54M 0.05%
+285,207
New +$2.83M
MMSI icon
73
Merit Medical Systems
MMSI
$4.54B
$3.48M 0.05%
+41,846
New +$3.64M
HAE icon
74
Haemonetics
HAE
$3.63B
$3.37M 0.05%
69,089
+65,560
+1,858% +$4.06M
HTFL
75
Heartflow Inc
HTFL
$2.19B
$3.37M 0.05%
+100,000
New +$3.21M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2025 Portfolio in Review

As of Q3 2025, Deerfield Management held 171 positions worth $6.55B, up 19% from $5.51B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q3 2025 filing shows 48 new, 43 increased, 20 reduced and 19 closed positions. Its largest new stake was Bristol-Myers Squibb: 2,337,771 shares worth $105M. The largest sale was Oscar Health, an estimated $250M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Real Estate and Financials.

  • Deerfield Management's largest Q3 2025 buy was Bristol-Myers Squibb: 2,337,771 shares worth $105M.
  • Deerfield Management added most to Centene in Q3 2025, an estimated $177M increase.
  • Deerfield Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $74.9M.
  • Deerfield Management fully exited Oscar Health in Q3 2025, selling an estimated $250M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.55B portfolio in Q3 2025.
  • Deerfield Management opened 48 new positions and closed 19 in Q3 2025.
  • Deerfield Management's portfolio value rose 19% quarter-over-quarter to $6.55B.

Based on Deerfield Management's 13F filing for Q3 2025, filed 14 Nov 2025.